By Max Bronstein and David Beier
This article ran in BioCentury on March 7, 2020
As the world eyes a return to post-COVID crisis ‘normalcy,’ a robust global recovery will depend on effective treatments and ultimately a vaccine. Yes, more than 400 research and clinical programs are already under way, but coordinating these efforts is a major challenge.
That’s why when NIH announced the formation of a public-private partnership among biopharmaceutical companies, the CDC, and global regulatory…